| Drug Name: | Praziquantel (55268-74-1) |
|---|---|
| PubChem ID: | 4891 |
| SMILES: | C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2 |
| InchiKey: | FSVJFNAIGNNGKK-UHFFFAOYSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 312.413 |
| LogP | : | 2.5349 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 40.62 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Chloroquine (54-05-7) | Reduced Pranziquantel Efficacy In Systemic Worm Infections Such As Schistosomiasis | Antagonistic | Not established | The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans |
| Phenytoin (57-41-0) | Neurocysticercosis Treatment Failures | Antagonistic | Not established | Phenytoin and carbamazepine decreased oral bioavailability of praziquantel |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category